Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01831726
Title Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Dovitinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST